Bromodomain inhibition reduces CDK6 expression and reverses CDK4/6 inhibitor resistance in ER plus breast cancer

被引：0
|
作者：
Liu, Renyan [1 ]
Pantelidou, Constantia [1 ]
Jadhav, Heta [1 ]
Shapiro, Geoffrey [1 ]
机构：
[1] Dana Farber Canc Inst, Boston, MA 02115 USA
来源：
CANCER RESEARCH | 2022年 / 82卷 / 12期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5649
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Preclinical head-to-head comparison of CDK4/6 inhibitor activity toward CDK4 vs CDK6
    Delach, Scott
    Caponigro, Giordano
    CANCER RESEARCH, 2021, 81 (04)
  • [32] Resistance mechanisms and therapeutic strategies of CDK4 and CDK6 kinase targeting in cancer
    Asciolla, James J.
    Wu, Xuewei
    Adamopoulos, Christos
    Gavathiotis, Evripidis
    Poulikakos, Poulikos I.
    NATURE CANCER, 2025, 6 (01) : 24 - 40
  • [33] Alteration in the expression of cdk4 and cdk6 proteins in oral cancer and premalignant lesions
    Poomsawat, Sopee
    Buajeeb, Waranun
    Khovidhunkit, Siribang-on
    Punyasingh, Jirapa
    JOURNAL OF ORAL PATHOLOGY & MEDICINE, 2010, 39 (10) : 793 - 799
  • [34] Co-targeting CDK2 and CDK4/6 overcomes resistance to aromatase and CDK4/6 inhibitors in ER+ breast cancer
    Abeer J. Al-Qasem
    Carla L. Alves
    Sidse Ehmsen
    Martina Tuttolomondo
    Mikkel G. Terp
    Lene E. Johansen
    Henriette Vever
    Luna V. A. Hoeg
    Daniel Elias
    Martin Bak
    Henrik J. Ditzel
    npj Precision Oncology, 6
  • [35] Co-targeting CDK2 and CDK4/6 overcomes resistance to aromatase and CDK4/6 inhibitors in ER+ breast cancer
    Al-Qasem, Abeer J.
    Alves, Carla L.
    Ehmsen, Sidse
    Tuttolomondo, Martina
    Terp, Mikkel G.
    Johansen, Lene E.
    Vever, Henriette
    Hoeg, Luna V. A.
    Elias, Daniel
    Bak, Martin
    Ditzel, Henrik J.
    NPJ PRECISION ONCOLOGY, 2022, 6 (01)
  • [36] The Role of CDK4/6 Inhibition in Breast Cancer
    Murphy, Conleth G.
    Dickler, Maura N.
    ONCOLOGIST, 2015, 20 (05): : 483 - U49
  • [37] Longitudinal, multimodal profiling of metastatic ER plus breast cancer on CDK4/6 inhibitor therapy
    Creason, Allison L.
    Egger, Julian
    Watson, Cameron
    Sivagnanam, Shamilene
    Lin, Jia-Ren
    Chin, Koei
    Sorger, Peter K.
    Coussens, Lisa M.
    Mitri, Zahi I.
    Gray, Joe W.
    Mills, Gordon B.
    Goecks, Jeremy
    CANCER RESEARCH, 2023, 83 (07)
  • [38] CDK4/6 inhibition in luminal breast cancer
    Gampenrieder S.P.
    Rinnerthaler G.
    Greil R.
    memo - Magazine of European Medical Oncology, 2016, 9 (2) : 76 - 81
  • [39] Breast cancer: CDK4/6 inhibitor plus fulvestrant prolongs survival
    Lorenz, Judith
    GEBURTSHILFE UND FRAUENHEILKUNDE, 2022, 82 (02)
  • [40] LncRNA TROJAN promotes proliferation and resistance to CDK4/6 inhibitor via CDK2 transcriptional activation in ER plus breast cancer
    Jin, Xi
    Ge, Li-Ping
    Li, Qiang
    Zhao, Naiqing
    Di, Gen-Hong
    Xu, Xiao-En
    Jiang, Yizhou
    MOLECULAR CANCER, 2020, 19 (01)
12345